Importance of PLD2 in an IL-23 driven psoriasiform dermatitis model and potential link to human psoriasis

• Published in: Journal of dermatology Vol. 50; no. 10; pp. 1321 - 1329
• Main Authors: Su, Zhi, Slivka, Peter, Paulsboe, Stephanie, Chu, Katherine, Wetter, Joseph B, Namovic, Marian, Perron, Denise, Kannan, Arun, Wan, Qi, Manning, Charlene, Todorovic, Viktor, Smith, Kathleen M, Lipovsky, Alex, Wang, Yibing, Frank, Kristine, McGaraughty, Steve, Loud, Jacqueline, Scott, Victoria E, Honore, Prisca, Goedken, Eric R
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.10.2023
• Subjects: Animal models; Calcium-binding protein; Cell differentiation; Chemokines; CXCL10 protein; Dermatitis; Ear; Gene expression; Helper cells; Hybridization; Lipopolysaccharides; Lymphocytes T; Macrophages; Phospholipase D; Phospholipase D2; Psoriasis; Skin diseases; Skin lesions; Splenocytes; psoriasiform dermatitis; IL-23; PLD1; psoriasis; PLD2
• ISSN: 0385-2407; 1346-8138
• DOI: 10.1111/1346-8138.16899

Phospholipase D2 (PLD2), a major isoform of the PLD family, has been reported to regulate inflammatory responses. Thus far, the relevance of PLD2 in psoriasis, an inflammatory skin disease, has not been explored. In the current study, we examined PLD2 expression in the skin of psoriasis patients and the role of PLD2 in an interleukin (IL)-23-induced mouse model of psoriasiform dermatitis. Both in situ hybridization and bulk RNA sequencing showed PLD2 gene expression is significantly higher in lesional relative to non-lesional skin of psoriasis patients or the skin of healthy subjects. PLD2 expression is also enriched in residual lesions from patients on biologic therapies. Murine in vivo studies showed that PLD2 deficiency significantly reduced psoriasiform inflammation in IL-23-injected ears, as reflected by decreases in ear thickness, expression of defensin beta 4A and the S100 calcium binding protein A7A, macrophage infiltrate, and expression of CXCL10 and IL-6. However, the expression of type 17 cytokines, IL-17A and IL-17F, were not reduced. Dual knockout of PLD1 and PLD2 offered little additional protection compared to PLD2 knockout alone in the IL-23 model. In addition, pharmacological inhibition with a pan-PLD1/PLD2 inhibitor also suppressed IL-23-induced psoriasiform dermatitis. Bone-marrow-derived macrophages from wild type (WT) and PLD2 knockout (KO) mice exhibited little difference in viability and sensitivity to lipopolysaccharide and/or interferon gamma, or resiquimod (R848). PLD2 deficiency did not alter the differentiation and function of Th17 cells in an ex vivo study with splenocytes isolated from WT and PLD2 KO mice. Overall, these data suggest that PLD2 may play a role in the pathophysiology of psoriasis. Reducing macrophage infiltrate and cytokine/chemokine production might contribute to an anti-inflammatory effect observed in PLD2 knockout mice. Further studies are required to better understand the mechanisms by which PLD2 contributes to skin lesions in psoriasis patients and psoriasiform dermatitis models.